All In Biotech

Drug Trial Radar · NCT04010305

Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia

A Phase Ib Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Determine Efficacy, Pharmacokinetics and Safety of BXCL501 in Agitation Associated With Schizophrenia

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 135 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

135

Actual

Start

May 22, 2019

Primary completion

Jul 31, 2019

Study completion Jul 31, 2019

Sponsor

Lead sponsor
BioXcel Therapeutics IncIndustry
Sponsor type
Industry
Collaborators
Cognitive Research Corporation
First posted
Jul 8, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two-stage adaptive Phase Ib trial design, that will identify two doses (lowest dose with clinical benefit and highest safe dose) in a first stage and better evaluate safety, tolerability and variability of effect in the second stage.

Conditions

  • Agitation
  • Schizophrenia

Interventions

  • Sublingual film containing BXCL501 (Dexmedetomidine)Drug

    Sublingual film containing BXCL501 (Dexmedetomidine) for the treatment of agitation associated with Schizophrenia

  • Placebo filmDrug

    Placebo film for BXCL501

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PANSS-EC Change From BaselineTime frame: 120 minutes

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • BioXcel Clinical Research Site

    Little Rock, Arkansas

  • BioXcel Clinical Research Site

    Cerritos, California

  • BioXcel Clinical Research Site

    Lemon Grove, California

  • BioXcel Clinical Research Site

    Long Beach, California

  • BioXcel Clinical Research Site

    Orange, California

  • BioXcel Clinical Research Site

    Miami Lakes, Florida

  • BioXcel Clinical Research Site

    Atlanta, Georgia

  • BioXcel Clinical Research Site

    Gaithersburg, Maryland

  • BioXcel Clinical Research Site

    Flowood, Mississippi

  • BioXcel Clinical Research Site

    Berlin, New Jersey

  • BioXcel Clinical Research Site

    Austin, Texas

  • BioXcel Clinical Research Site

    Richardson, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.